Podcasts about Lung cancer

People who ate the most ultraprocessed foods had a 41% higher risk of developing lung cancer compared with those who ate the least The increased risk was seen in both smokers and nonsmokers, showing that diet alone influences lung cancer development Processed foods alter nutrient absorption, strip away protective compounds, and add toxic byproducts that fuel inflammation and immune dysfunction Harmful chemicals from packaging and high-heat cooking further raise cancer risk and weaken your body's defenses Choosing whole, unprocessed foods and cutting linoleic acid in vegetable oils down to 2 grams or less daily is one of the most effective ways to protect your lungs

Featuring an interview with Dr Jacob Sands, including the following topics: Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract  Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623. Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23) Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.  Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12) Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501. Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521. Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11) Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract CME information and select publications

The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC. 1. The COMPEL study tries to find the value of continuing osimertinib (with the addition of chemotherapy) after progression on osimertinib. The results are, well, compelling! 2/3. We now have updates on the OS benefits of osimertinib + chemotherapy (FLAURA2) and amivantamab + lazertinib (MARIPOSA) compared to osimertinib monotherapy in initial treatment of metastatic disease. 4. NEOADAURA tries to determine if neoadjuvant osimertinib has value, but longer follow-up will be needed to assess this practice.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Alona Zer moderates a discussion in Hebrew about highlights from the conference with Dr. Haitam Nasrallah, Dr. Jair Bar, and Dr. Ory Wiesel.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about highlights from the conference with Dr. Laura Mezquita and Dr. Jorge Alatorre Alexander.

JCO fellow Dr. Ece Cali speaks with JCO Associate Editor Dr. Thomas E. Stinchcombe to discuss the JCO article "Phase 2 Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)", that was simultaneously released at the IASLC 2025 World Conference on Lung Cancer. TRANSCRIPT Dr. Ece Cali: Hello, and welcome to our series where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's most important oncology meetings. I am your host, Dr. Ece Cali, JCO editorial fellow, and I am joined by Dr. Tom Stinchcombe, JCO associate editor, to discuss the Journal of Clinical Oncology article and 2025 World Conference on Lung Cancer abstract presentation, “Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations.” The WU-KONG1B trial is a multinational, phase II study that investigated the efficacy and safety of different doses of sunvozertinib in patients with metastatic non-small cell lung cancer and EGFR exon 20 insertion mutations after progression on platinum based chemotherapy. Tom, before we dive into the results, could you walk us through the rationale for this study, and how does it fit into the current treatment options for patients with EGFR exon 20 insertion? Dr. Tom Stinchcombe: Thank you, Dr. Cali. I think the clinical context is always important. We have known that EGFR exon 20 insertions exist and that they are resistant to our currently available EGFR tyrosine kinase inhibitors, and I think there have been attempts in the past to develop a tyrosine kinase inhibitor, but there is a very narrow therapeutic window between the dose you need to inhibit the EGFR mutation in the cancer and the EGFR receptor on normal tissues, most notably the mucosa, the gut, and the skin. And so, our previous attempts have failed largely because the dose required was not tolerable for patients and they could not really stay on the drug for a long time or they were not very active. And so, I think there was a real desire to develop an EGFR tyrosine kinase inhibitor, and then, historically, the standard had been a platinum based doublet as the standard of care. And more recently, platinum based doublet with amivantamab has proven to be superior to platinum based chemotherapy alone. I think the context is also important that amivantamab is not necessarily available in all the countries, and so, there are patients who do not have access to amivantamab. Going to the rationale, I think that this drug had shown preliminary promise of having activity but without that being encumbered by those EGFR wild type toxicities, and, therefore, it was really explored in this larger study. Dr. Ece Cali: And what are some key findings from this trial? Dr. Tom Stinchcombe: So, I think that we should look at the study design. It is a little quirky, for lack of a better term, in that there is a randomization to 200 versus 300 mg, and then, there was a nonrandomized cohort of 300 mg. So, when you look at the study, if you are a purist, you will just look at the randomized patients. If you are sort of an aggregator, you look at all patients. So, it shows reporting on three cohorts, but I think the key findings are that the 200 mg and the 300 mg treatments had similar toxicities in terms of response rate, duration of response, and progression free survival. And as you know going through the review, there was a lot of queries from the reviewers as to which would be the preferred dose, and to me, I think this really illustrates a dose finding component to a trial design because there is a lot of debate about what the minimal effective dose is or the optimal dose. And in this case, having the two dose cohorts did provide us some valuable efficacy and toxicity information. And then, when I look at the study, I want to make sure it reflects my patient population, and about a quarter of patients had brain metastases, and about 15% had previous amivantamab, and about 5% to 10% had another EGFR tyrosine kinase inhibitor. Dr. Ece Cali: And what is the objective response rate and the duration of response? These are pretty good numbers for this patient population. Dr. Tom Stinchcombe: In the 200 mg cohort, it was about 46%. The duration of response was around 11 months, and the PFS was around 8 months. The 300 mg cohort was 46%, duration of response 9.8, and the median PFS is 6.9 months, and I think that this is greater activity than we have seen with our previous attempts at EGFR tyrosine kinase inhibitors. Dr. Ece Cali: And based on these data, FDA granted accelerated approval for sunvozertinib very recently at 200 mg once daily dosing in this setting. So, that is a major step forward for our patients. Dr. Stinchcombe, how does this impact your clinical practice, and what side effects should oncologists be watching for if they prescribe this medication? Dr. Tom Stinchcombe: So, I think it was very interesting that they chose the 200 mg dose, which I think was more tolerable, and when we kind of look at this, there still was a rate of diarrhea, all grade, rash, paronychia, which are the EGFR related toxicities. There can be some decreased appetite, stomatitis, and then, it can lead to some lab abnormalities, like increased CPK and creatinine that physicians have to be aware of. You know, how it will affect my practice is that all these patients had received a platinum based chemotherapy as the first line therapy. I think that this would become my preferred second line therapy for patients outside the context of a trial because of the activity and the tolerability. Dr. Ece Cali: And lastly, several other tyrosine kinase inhibitors are being evaluated for EGFR exon 20 insertion, including in the frontline setting. So, what are some of the outstanding questions in this space, and what data should our listeners keep an eye on moving forward? Dr. Tom Stinchcombe: I think you are right that now, there is going to be another EGFR tyrosine kinase that may become available in the next year, and there is another drug, furmonertinib, that is being investigated. I think, for the clinical question, is, well, can we move these into the first line setting? And actually, the development path has two ways of doing this. There is EGFR tyrosine kinase compared to platinum based chemotherapy, and then, platinum based chemotherapy with an EGFR tyrosine kinase versus platinum based chemotherapy, and both have their merits and strengths. And so, I think it is going to be very interesting as we see if those first line trials, one, can they be demonstrated to be superior to platinum based chemotherapy, and then by what magnitude and what the side effects are. But I think we are hoping that in the next couple of years, we will have an additional first line option for our patients. Dr. Ece Cali: Yeah, it is always great to have more options for our patients. Thank you, Dr. Stinchcombe, for speaking about the JCO article, “Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations.” Join us again for the latest JCO simultaneous publications. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of World Lung Conference. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about highlights from the conference with Dr. Yang Xia and Dr. Nan Bi.

Lung cancer remains one of the leading causes of cancer-related death, yet many cases occur in people who have never smoked. One often-overlooked culprit is radon, a naturally occurring radioactive gas and the second leading cause of lung cancer.

Dr. Halmos from Montefiore in New York shares his views on the most impactful practice changing or informing data for lung cancer from the ASCO 2025 meeting.

n this episode of Conversations in Lung Cancer Research, A/Prof Tim Clay discusses the multidisciplinary management of CNS metastases in the context of thoracic cancers. Joined by Dr. Keryn Davidson, a consultant neurosurgeon, and A/Prof Fiona Hegi Johnson, a radiation oncologist, the discussion focuses on the nuances of treating patients with non-small cell lung cancer presenting with brain metastases. Key topics include the role of neurosurgery, decision-making for radiation therapy, evolving approaches for oncogene-driven cancer patients, management of radiation necrosis, and the complexities of treating small cell lung cancer and leptomeningeal disease.  This episode is sponsored by Pfizer.(00:00) Introduction and Acknowledgements(00:35) Meet the Experts(01:44) Neurosurgery in CNS Metastases(07:00) Radiation Therapy Insights(13:59) Oncogene-Driven Lung Cancer(25:14) Challenges in Small Cell Lung Cancer(29:56) Advanced Treatment Strategies(32:23) Future Directions and Conclusion

After experiencing a persistent cough and a pain in his side, Keith Jay of Texas was encouraged to seek medical advice. Although it took a few months, in November of 2024 he was diagnosed with stage 4 lung cancer that had metastasized to his lymph glands, bones and spine. Refusing chemotherapy, a friend encouraged him to contact Corrie Yelland who told him about cannabis oil. Nine months later he is cancer free. A truly inspirational story. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

In this JCO Article Insights episode, Dr. Joseph Matthew interviews authors Dr. Yang Zhang and Dr. Haiquan Chen about their recently published JCO article, "Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma" TRANSCRIPT Joseph Mathew: Welcome to the Journal of Clinical Oncology Article Insights episode for the August issue of the JCO. This is Joseph Mathew, editorial fellow for JCO, and today, it is my pleasure to have with us Dr. Haiquan Chen and Dr. Yang Zhang, authors of the recently published manuscript, "Phase 3 Study of Mediastinal Lymph Node Dissection for Ground-Glass Opacity-Dominant Lung Adenocarcinoma," which we will be discussing today. Dr. Chen is the Director of the Institute of Thoracic Oncology at Fudan University and the Chief of Thoracic Surgery at Fudan University Shanghai Cancer Center, where he is also the Head of Thoracic Oncology MDT and the Director of the Lung Cancer Center. Dr. Chen is a surgeon-scientist and a pioneer in developing individualized surgical strategies for early-stage non-small cell lung cancer. Dr. Zhang is a surgical oncologist and a member of the team which Dr. Chen leads at the Fudan University Shanghai Cancer Center. Welcome Dr. Chen and Dr. Zhang. Thank you very much for accepting our invitation and joining us today as part of this podcast episode. To summarize the salient points, this study presented the interim analysis of a multi-center, open-label, non-inferiority, randomized controlled trial investigating the necessity of systematic mediastinal lymph node dissection at the time of segmentectomy or lobectomy in patients with clinical stage T1N0M0 ground-glass opacity-dominant invasive lung adenocarcinoma, as defined by a consolidation-to-tumor ratio of 0.5 or less on thin-section computed tomography and a maximum tumor diameter of 3 cm or less. Eligible participants with intraoperatively confirmed invasive adenocarcinoma on frozen section analysis were randomized to either the systematic mediastinal lymph node dissection arm or to no mediastinal lymph node dissection. In the latter experimental group, mediastinal lymph nodes comprising the N2 nodal stations were not dissected, and the hilar nodes were variably addressed at the discretion of the operating surgeon. The primary endpoint of the trial was disease-free survival at 3 years. Secondary endpoints included perioperative outcomes, the status of lymph node metastasis in the systemic lymph node dissection arm, and 3-year overall survival. Before the trial reached its accrual target, a pre-planned interim safety analysis set for the time point when enrollment reached 300 patients was performed. It was noted that while none of the patients in either arm had nodal metastasis on postoperative pathological evaluation, lymph node dissection-related intraoperative and postoperative complications were more commonly observed in the systematic lymph node dissection arm, including one life-threatening episode of massive bleeding. Since this met the predefined criteria for trial termination, and in accordance with the principle of non-maleficence, further recruitment was stopped and the trial terminated. Although the 3-year disease-free survival and the overall survival for the enrolled patients were comparable, operative outcomes, including the duration of surgery, blood loss, chest tube duration, length of postoperative stay, and the rate of clinically significant complications, were significantly lower in the experimental arm compared with the systematic lymph node dissection group. The authors concluded that for well-selected patients, mediastinal nodal dissection could be omitted without adversely affecting oncological outcomes, representing a significant shift in current surgical practice, given that guidelines the world over recommend systematic lymph node dissection or sampling for all invasive lung cancers. In summary, this study addressed a clinically relevant question with regard to the extent of nodal dissection, especially in the light of recent evidence recommending less extensive parenchymal dissections for early-stage non-small cell lung cancer, with the findings suggesting that invasive lung adenocarcinoma associated with ground-glass opacities of consolidation-to-tumor ratio up to 0.5 was an excellent predictor of tumor biology, and in clinical T1N0M0 lesions, a reliable predictor of negative mediastinal lymph node involvement. So Dr. Chen and Dr. Zhang, could you tell us some more about what led you to do this research and the challenges which you faced while recruiting patients for this trial? Dr. Yang Zhang: Dr. Mathew, thank you for your summary. The current clinical guidelines recommend systematic lymph node dissection or sampling for every patient with early-stage lung cancer, regardless of their lymph node status. And in our clinical practice, we observe that this procedure causes a lot of surgical complications including chylothorax and recurrent laryngeal nerve injury. Furthermore, dissecting the tumor-draining lymph nodes actually may potentially damage the body's anti-tumor immunity. So, Dr. Chen proposed the concept of selective lymph node dissection, which we aimed to dissect the metastatic lymph nodes, while at the same time we try to preserve as many uninvolved lymph nodes as possible. So previously, we have conducted a series of retrospective studies to identify reliable predictors of nodal negative status in certain mediastinal zones, and we have performed a prospective observational phase 2 clinical trial to validate that the six criteria we proposed are 100% in predicting node-negative status. And this forms the basis for our phase 3 clinical trial. Dr. Haiquan Chen: This trial is only one of the series of trials. The meaning of this trial you already said. And for a long time, from the surgeon's point of view, we considered minimally invasive surgery. It minimizes the size of the incision and minimizes the number of the holes we made. So, the true and the high-impact of minimally invasive, we make a concept of minimal dissection, that means organ-level minimally invasive. So we proposed the concept of minimally invasive 3.0, that means minimal incision, minimal dissection (that means organ-level minimal), and systemic minimally invasive. So at first, we judged from the point of minimally invasive surgery. As long as immunotherapy is widely used in the clinical practice, we know immunotherapy, that means you use drugs to stimulate and activate the lymph node site. If we dissect all the metastatic lymph nodes, cut them out, how can we restimulate that lymph node site? So, from minimally invasive trauma and second, from the functional aspect, to try to save as many uninvolved lymph nodes as possible. Joseph Mathew: Thank you, Dr. Chen. That's a very interesting concept that you alluded to even in the discussion of this paper, as to the potential role of the non-metastatic lymph nodes as immune reservoirs. So, coming back to this paper, were there any challenges which you faced while recruiting patients for this trial? Dr. Haiquan Chen: The criteria is very clear. That means invasive adenocarcinoma, that means most of the centimeter is 3.0 centimeter and also CTR ratio less than 0.5. And we can see that, you know, we did study about that. Even the invasive component of the subsolid nodule, it's bigger than the solid part. That means even the pure GGO, we can find out that there's still some invasive component. From this point of view, pure GGO and subsolid GGO, from this part of invasive carcinoma, that means it's a special clinical subtype that we, from retrospective study and also prospective study, we find out this group of patients, there are no mediastinal lymph node metastasis. So I think it's very important for this kind of group that we can avoid doing the mediastinal lymph node dissection. And we can do organ-level minimally invasive surgery. And also, we try to keep the patient's immune function as normal as possible. Dr. Yang Zhang: Well, Dr. Mathew, we believe that the biggest challenge when we are enrolling these patients is that there needs to be a paradigm shift in the mind because systematic lymph node dissection has long been the standard of care. And some patients may misunderstand. Before the enrollment, we have to give them informed consent, but if the patient hears that they may be enrolled in the no-lymph-node-dissection group, they may feel that they do not receive radical, curative-intent surgery. So we believe, as Dr. Chen has said, after the release of our results, the no-lymph-node dissection may be incorporated in the future guideline for those patients without lymph node involvement, we can just omit the lymph node dissection. Joseph Mathew: The study described two pre-planned interim points during the course of subject enrollment when the data was analyzed. So Dr. Chen and Dr. Zhang, could you please explain a little more about these two interim points of analysis that were planned and the rationale behind it? Dr. Yang Zhang: When conducting this trial, we have two concerns. One is if there is any lymph node metastasis, there may be omission of metastatic lymph nodes not dissected in the no-lymph-node-dissection group. And there is another concern is that if all these lymph nodes are uninvolved, then dissecting these lymph nodes may cause life-threatening complications. So, we set the 150 interim analysis to ensure that there is no lymph node involvement in this group. And the other early termination criteria is set because if there is no lymph node involvement found in both groups, then a severe complication which is life-threatening is unacceptable because it threatens the patient's safety. Joseph Mathew: So, although you did briefly allude to in the paper, what was the basis for selecting DFS as the primary endpoint when the objective of this trial was to assess nodal involvement in this subset of tumors? Dr. Yang Zhang: Well, previously, we have done a series of retrospective studies and one prospective phase 2 trial. And in these studies, we have identified that GGO-dominant lung adenocarcinoma, even if it's invasive, it has no lymph node involvement. So this phase 3 trial was primarily designed to compare the survival outcomes. But as the trial went on, as Dr. Chen has concerns that if the patients have no lymph node metastasis at all, it may be unfair to dissect the lymph nodes for patients enrolled in the systematic lymph node dissection group. So there is one life-threatening complication that happens due to dissecting the lymph nodes and injury to the superior vena cava, which leads to massive bleeding. It is at this point that we decided to terminate this trial for patient safety concerns. Joseph Mathew: Yeah, that's a very fair point. So you made sure that the ethical considerations were kept intact. So another point was, there was a mention in the study of the historical data from your institution suggesting a 3-year disease-free survival of 96.6% for patients with clinical T1N0M0 ground-glass opacity-dominant invasive lung adenocarcinoma. So could you please elaborate on the patterns of recurrence which you noted for this group of patients who had developed a recurrence? Dr. Haiquan Chen: Yeah, I think over 90% 3-year DFS, that's the least. From our retrospective data for this kind of group of patients, their DFS is so good. To the best of my knowledge, almost 100%. So this is very conservative, 94, 90% is very conservative. I think the trial eventually would have been positive. It's a special clinical subtype, even for invasive adenocarcinoma, their prognosis is much better than the other type of invasive adenocarcinoma. Joseph Mathew: So this question may be slightly outside the purview of this study, but in your clinical practice, would you advocate either segmentectomy or lobectomy for all patients meeting the trial criteria, that is, lesions measuring 3 cm or less with a CTR of up to 0.5? Or is there a subgroup of patients you would recommend a wedge dissection for? Dr. Haiquan Chen: I think CTR ratio is one parameter and also the location is another very important parameter. So we put it together to make a decision, the patient should do a lobectomy or segmentectomy. Even for an ongoing trial, for even the patient, invasive adenocarcinoma, we can do in the right location, even wedge, it can achieve enough negative margin in the ongoing trial to verify the comparable result for the patient, we can do the wedge dissection. So not just the CTR ratio, that's not the only parameter to make a decision on what kind of procedure we'll do. Joseph Mathew: Yeah, great point, Dr. Chen. So from my perspective, this study was a well-designed, randomized control trial based on a relevant and clinically valid research question. So what, in your opinion, are the main strong points of this study? Dr. Yang Zhang: We believe that this study represents the first randomized clinical trial published, yet, regarding the topic of selective lymph node dissection. It basically offers the highest level of evidence. We believe our results should be incorporated in the future clinical guideline. Joseph Mathew: Given the increasing incidence of these lesions, I think it was- a randomized control trial in this arena was much awaited. And the other point is that GGO-dominant lung adenocarcinomas, the specific clinical guidelines are not very clear. So I think your study brought out that lymph node dissection for these tumors which satisfy the eligibility criteria could be omitted safely. Important consideration here is that the conclusions of the trial were based on an interim analysis, and this analysis was not planned for an early assessment of the primary endpoint. In other words, the study was not adequately powered to detect a significant difference in DFS at 3 years. So Dr. Chen and Dr. Zhang, what do you perceive are the most important limitations of this study which you feel should be addressed in future research? Dr. Haiquan Chen: So the surgery now is more individualized. I think the surgery from the last two decades, from the maximum tolerable intervention to minimum effective treatment, there's a big shift. So I think that the consensus, we can preserve normal lung parenchyma as much as possible. For the lymph nodes, I think that the big shift, we should shift it to keep as many as uninvolved lymph nodes as possible. So that's very important, not just to reduce the intraoperative trauma, but also to keep the immune environment as normal as possible. Joseph Mathew: Another point was the limited long-term follow-up data to determine the actual impact of omitting lymph node dissection on local-regional disease control. So is any future follow-up planned to assess the long-term survival outcomes for the 302 patients which were enrolled in this trial? Dr. Haiquan Chen: Yeah, I think that's very important for us. This trial we terminated just because if we keep the trial going, it's unfair for the mediastinal lymph node dissection group. We tried to just stop here, and we shifted to the single-arm trial. So, 2 or 3 years, this trial and another trial, they will give our final result to demonstrate more if selective mediastinal lymph nodes have a better result than ever before. And we will support the mediastinal lymph node dissection. That's one way. And the American College just asked me, how can we put this policy into clinical practice in the United States? Because most of the patients they meet have solid tumors. So we have another trial, try to figure out how we can make sure before and intraoperative the lymph node status is negative or positive, and then we can solve that problem and put this policy into clinical practice in the Western society. Joseph Mathew: Great. So that would be something we should all be looking forward to. So, this brings me to the final point of discussion on future research in this field. Dr. Chen, you commented in the paper that future studies should focus on improving the reproducibility of CTR evaluation. What are your thoughts on this subject? Dr. Haiquan Chen: The CTR ratio, the concept from the JCOG 0201, just a concept from that prospective study, the phase 2 study, only subgroup analysis they give the concept of CTR ratio and the diameter. How can we reproduce? In our group and also I believe in Japan and in China, in Korea, and in our daily practice, I think CTR ratio is not a big issue. There are two very important things. One, you make sure the CTR ratio, not in a common CAT scan, but in a high-resolution CAT scan. So the imaging, that's the first thing. And the second, not from the single section and a two or three section, you make sure that your calculation is accurate. That's not just the single section, you make sure that you got the conclusion, the CTR ratio is the same number. We make sure that totally we, from the top to the bottom of the whole lesion, we make sure that the CTR ratio is accurate. Joseph Mathew: Thank you, Dr. Chen. I think that would involve training our radiologists also to be aware of the CTR ratio and how it should be interpreted. So another very interesting concept which you had alluded to in the discussion was the potential role of non-metastatic lymph nodes as immune reservoirs. So how do you think we could preserve these nodes and do you think sentinel node biopsies would play a role in future? Dr. Yang Zhang: Actually, Dr. Chen has also led some basic research on this topic. We are investigating the immunological role of the tumor-draining lymph nodes. And our preliminary results have already shown that the tumor-draining lymph nodes of lung cancer, especially those uninvolved lymph nodes, have a vital role in the anti-tumor immunity and also effective response to the current anti-PD-1 immunotherapy. In the future, we believe that by incorporating our clinical evidence and those findings from our basic research, we will be able to provide very strong rationale to support selective lymph node dissection. Joseph Mathew: So lastly, what are the questions that still remain to be answered and what do you perceive as the next step in this field? Dr. Haiquan Chen: I think for the lung cancer surgery, especially for the cT1N0M0, they are more individualized. We can, based on the patient, the location, the CTR ratio, we can do wedge dissection, or segmentectomy, or lobectomy. For the lymph node dissection, we can do no mediastinal lymph node dissection or selective, only to dissect the positive one, or we have to do the systemic mediastinal lymph node dissection. So we can see there are too many combinations. So in the near future, for the surgery perspective, we have it more individualized. In the future, we just try to make sure we do not cut as many as possible. We just make sure that we can avoid over-diagnosis or overtreatment or over-dissected. I think that in the near future, that goal will come true. Joseph Mathew: That's a great point, Dr. Chen. So that would be something also for the thoracic oncology community to work towards. This wraps up today's episode of JCO Article Insights. Dr. Chen and Dr. Zhang, thank you very much for taking the time to join us today in what has been a very insightful session. Dr. Haiquan Chen: Thank you. Dr. Yang Zhang: Thanks. Joseph Mathew: To our audience, thank you for listening. Please stay tuned for more interviews and articles, summaries, and be sure to leave us your comments and ratings. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In this episode, Dr. Paul Wheatley-Price chats with Dr. Adrian Sacher on everything there is to know about KRAS lung cancer. What is KRAS lung cancer, how is it tested, and what it means in terms of treatment options for those who have this subtype of lung cancer. Dr. Adrian Sacher is a Thoracic Medical Oncologist at the Princess Margaret Cancer Centre and Assistant Professor in the Departments of Medicine & Immunology at the University of Toronto.

An update on natural thyroid availability and the FDAA correction on disseminated sarcoidosis and stressI'm a former smoker. Should I be concerned about beta carotene in the Alpha Base multivitamin?A comment from a user of lithium orotate for the last eleven yearsDoes long-term use of Horse Chestnut cause a thiamin deficiency?

Thursday, July 10th, Jeffrey Mosher was on the road to UM Health-Sparrow Lansing, 1215 E. Michigan Ave., Lansing, Michigan. The celebration was regarding University of Michigan Health-Sparrow just completing its 500th ION robotic bronchoscopy, an innovative procedure that allows clinicians to maneuver a robotic-assisted catheter into the lungs to target hard-to-reach nodules. It means we're able to reach small or remote nodules that may contain the first signs of lung cancer and then address the cancer before it spreads. UM Health-Sparrow was the first hospital in the region to use ION and we're ready to celebrate our 500th milestone. A patient whose cancer was detected at an early stage will be available to discuss how ION changed his life, plus physicians will talk about the impact of the procedure. For this video, you see the room with procedures, interviews with Dr. Mohanad M. Saleh, MD Pulmonary Disease, Critical Care Medicine, Interventional Pulmonology and then patient Dan, an example of one of the 500 treated at UM Health-Sparrow with the ION robotic bronchoscopy process. Other footage from the conference room celebration of the 500 process milestone. » Visit MBN website: www.michiganbusinessnetwork.com/ » Watch MBN's YouTube: www.youtube.com/@MichiganbusinessnetworkMBN » Like MBN: www.facebook.com/mibiznetwork » Follow MBN: twitter.com/MIBizNetwork/ » MBN Instagram: www.instagram.com/mibiznetwork/

Thriving 10 Years After Lung Cancer Dr. Madeleine Long Shares Her Story with Dr. Michael Klaper by Chef AJ

Lung Cancer Considered--STK11 and KEAP1 as resistance mechanisms to immunotherapy by IASLC

In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain welcome Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, to discuss the recent FDA approval of Dato-DXD (datopotamab deruxtecan) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC). Key Topics: •⁠  ⁠Overview of Dato-DXd and its FDA approval •⁠  ⁠Mechanism of action and study design of the TROPION Lung trials •⁠  ⁠Efficacy and safety profile of Dato-DXd •⁠  ⁠Management of side effects and clinical pearls •⁠  ⁠Treatment sequencing for EGFR-mutated NSCLC Join us as we dive into the details of the TROPION Lung trials that led to this significant approval, the mechanism of action of Dato-DXd, and the implications for patients with various EGFR mutations.  Dr. Sands shared insights on the study design, efficacy, and tolerability of this new antibody-drug conjugate, as well as important clinical pearls for managing side effects such as stomatitis, dry eyes, and interstitial lung disease (ILD). We also explored the current treatment landscape for EGFR-mutated NSCLC, including the sequencing of therapies and the potential role of Dato-DXd in clinical practice. Tune in for an informative discussion that highlights the exciting advancements in oncology and the hope they bring to patients. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!

LCC in Cantonese: Novel Treatment for Advanced EGFR Mutant Lung Cancer by IASLC

Lung Cancer Update The Treatment Path I've Chosen with Dr. Matthew Lederman by Chef AJ

Lung cancer, particularly non-small cell lung cancer (NSCLC), is the deadliest cancer worldwide. Cigarette smoking is one of the main causes, but not every smoker develops the disease. This suggests that other biological factors help determine who develops cancer. Researchers from the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis, and from the Richard L. Roudebush Veterans Affairs Medical Center have now found that cigarette smoke, combined with a weakened DNA repair system, can trigger the early stages of lung cancer, particularly NSCLC. This work, led by first author Nawar Al Nasralla and corresponding author Catherine R. Sears, was recently published in Volume 16 of Oncotarget. Full blog - https://www.oncotarget.org/2025/08/11/cigarette-smoke-and-weak-dna-repair-a-double-hit-behind-lung-cancer-risk/ Paper DOI - https://doi.org/10.18632/oncotarget.28724 Correspondence to - Catherine R. Sears - crufatto@iu.edu Video short - https://www.youtube.com/watch?v=UEiCz834a8c Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28724 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC) To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

AITA: For telling my friend to stop turning her hobbies into side hustles? DIRT ALERT: Brooke Hogan shares why she didn't go to Hulk Hogans funeral, we talk A Breath of Hope Lung Cancer Walk & Run, and intergenerational summer camp See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Lung cancer remains one of the deadliest cancers in the United States, in part because it’s often detected too late. On The Spark, UPMC Thoracic Surgeon Dr. Troy Moritz joined the show to shed light on who should be screened, what symptoms not to ignore, and how technology is changing the way lung cancer is detected and treated. Who Should Be Screened? Dr. Moritz emphasized the importance of lung cancer screenings for a specific group:“We’re looking for people that are age 50 to up to 80 years of age and those people that have smoked what we consider to be 20 pack years,” he explained.That includes anyone who smoked a pack a day for 20 years — or an equivalent amount — and hasn’t quit within the last 15 years. These high-risk individuals are encouraged to undergo low-dose CT scans, which Dr. Moritz described as simple and noninvasive.“It’s pretty much just get in the CAT scan machine and buzz in, buzz out,” he said. “It’s not an MRI, so you don’t have to worry about that claustrophobic feeling.”Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

RaeAnn Tucker from the Henry and Stark County Health Departments and First Choice Healthcare Clinics joined Wake Up Tri-Counties to talk about National Breastfeeding Awareness Week, Radon Testing for Lung Cancer Day, swimming safety, CPR classes, and insurance navigators in Galva and Geneseo. August marks Breastfeeding Awareness Month, and the Henry and Stark County Health Departments—together with First Choice Healthcare—highlight programs supporting local families. WIC agencies and peer counselors stress breastfeeding's health, nutritional, and environmental benefits, offering guidance at 309-852-5272 and online. With World Lung Cancer Day on August 1, officials urge residents to test homes for radon, a leading cancer risk; radon kits are available at health department offices. Meanwhile, summer safety reminders emphasize swimming supervision and CPR skills, with certification classes offered monthly. Health insurance navigators will assist residents at multiple county events, and back-to-school physicals are available by appointment at local clinics.

LCC in Romanian: Management of Unresectable, EGFR-mutated Stage III Lung Cancer in Romania by IASLC

In this episode of the Southern Medicine Podcast, Loretta Loftus, MD, MBA, Vice Chair, Department of Breast Oncology at Moffitt Cancer Center, speaks with Lary Robinson, MD, a thoracic surgeon at Moffitt Cancer Center. Dr. Robinson reflects on his path to thoracic surgery, how the field has evolved, and key advances in lung cancer treatment—including the promise of immunotherapy and the importance of early screening. The conversation also touches on multidisciplinary care, as well as advice for primary care providers.

Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Francis Spruit, born in Djakarta, Indonesia, June 1959 The Netherlands - USA dual citizen Married to my high school sweetheart Roslyn Four kids and seven grand kids! Technology Program Manager, a mere two months away from retirement. Diagnosed December 2007 with Non Small Cell Lung Cancer, Stage 1B Treatment: right upper lobectomy on Christmas Eve 2007. Four cycles of Cisplatin and Etoposide chemotherapy in the spring of 2008. No active treatment since then. Annual chest CT scans to ‘keep an eye on things'. Actively advocating for the lung cancer community since 2012. Making our representatives in DC aware of the significant funding inequity of Lung Cancer research. Ready to enjoy retired life in Northern California and the Algarve. Transforming your health is more fun with friends! Join Chef AJ's Exclusive Plant-Based Community. Become part of the inner circle and start simplifying plant-based living - with easy recipes and expert health guidance. Find out more by visiting: https://community.chefaj.com/

Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of deaths because it is often diagnosed too late. A new screening program has become available from July 1 that hopes to detect cases much earlier for those at the highest risk - which includes Indigenous Australians and some migrant communities. - 肺がんは、オーストラリアで5番目に多く診断されているがんですが、発見が遅れることが多く、がんによる死亡原因の中で最も多くなっています。こうした中、7月1日から新たな肺がんの検診プログラムが始まりました。

On December 5, 2025, we will kick off the IASLC ASCO 2025 North America Conference on Lung Cancer. Guest include Dr. Ramesh Rengan, the Peter Wootton Professor and Chair of Radiation Oncology at the University of Washington and Senior Vice President of the Fred Hutchinson Cancer Center and Dr. Kristen Marrone, Associate Professor of Oncology and Director of the Medical Oncology and Hematology Fellowship Program at Johns Hopkins University.

Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information and select publications here.

Featuring perspectives from Prof Marina Chiara Garassino, Dr John V Heymach, Prof Solange Peters and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (0:00) Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters (2:07) Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino (26:30) Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands (50:19) Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach (1:12:36) CME information and select publications

Jesus Delivered Us (5) (audio) David Eells – 7/16/25 Saints, I want to point out to you that if you want deliverance from any demon, do not put the responsibility for the sin upon the demon. What did Peter say to Ananias and Sapphira? (Act.5:3) … Ananias, why hath Satan filled thy heart to lie to the Holy Spirit …? Was Peter blaming the lying spirit, or was he blaming Ananias? Some people have demons they inherited through the bloodline (Exodus 20:5, 34:7; Numbers 14:18; Deuteronomy 5:9), but we are born in sin. Psa 51:5  Behold, I was brought forth in iniquity; And in sin did my mother conceive me.  If you have a demon because of what you have done, guess what? You are still guilty. The Bible does not let you get off without being guilty. So the solution is 1Jn 1:9  If we confess our sins (not the demons sins), he is faithful and righteous to forgive us our sins, and to cleanse us from all unrighteousness.  (Pro.26:2) As the sparrow in her wandering, as the swallow in her flying, So the curse that is causeless alighteth not. See, there are people who just run from ministry to ministry looking for somebody to give them deliverance, but they will not first repent. They think all they need is deliverance, but God says they need to repent, because you can get delivered of anything and everything if you repent and believe. So there may be things you have never been delivered of yet, but God's plan is to deliver you from lusts of the flesh and demon spirits that take advantage of them. Let's look at some Old Testament types and shadows about delivering the Promised Land that show us the way God leads us from the time we come to know Him. This “house,” your body, is supposed to be ruled over by the spiritual man, and for that to happen, the carnal man who lives in your house has to be driven out and killed. This is a type of taking the Promised Land. Those Israelites represent the spiritual man, and those Canaanites represent the carnal man. God told them the Canaanites had to be driven out and killed, and the Israelites had to live in their houses. God said in (Deu.7:2) And when the Lord thy God shall deliver them up before thee, and thou shalt smite them; then thou shalt utterly destroy them: thou shalt make no covenant with them, nor show mercy unto them. And He also commanded, (Exo.23:33) They shall not dwell in thy land, lest they make thee sin against me; for if thou serve their gods (demons), it will surely be a snare unto thee. You see, if you leave one of the lusts of the flesh in your land, it is going to cause you to sin, so don't leave them and don't bow down to their gods. (Exo.23:20) Behold, I send an angel before thee, to keep thee by the way, and to bring thee into the place which I have prepared. By the way, you have an angel, too, as the Bible says in (Heb.1:14) Are they not all ministering spirits, sent forth to do service for the sake of them that shall inherit salvation? These spirits are with us to bring us into this salvation that Jesus provided. Exodus 23 is an exact parallel. (Exo.23:21) Take ye heed before him, and hearken unto his voice; provoke him not; for he will not pardon your transgression: for my name is in him. God's Name, which is His Nature, Character, and Authority, is in those angels. His Nature is so strong in them that they are perfect prophets for the Lord, and when an angel speaks to you, he speaks to you with the Voice of God. In the Book of Acts, Stephen said it was an angel who spoke out of the burning bush to Moses. (Acts 7:30) And when forty years were fulfilled, an angel appeared to him in the wilderness of Mount Sinai, in a flame of fire in a bush. An angel spoke to Moses with the Voice of God. (Exo.23:22) But if thou shalt indeed hearken unto his voice, and do all that I speak; (We see the Lord is speaking, but it is the angel's voice.) then I will be an enemy unto thine enemies. If you obey His Voice, He will be an enemy to your enemies. If you do not obey His Voice, He is not going to be an enemy to your enemies. You may run around everywhere looking for your deliverance from flesh and spirit, but you will fail when you are not obeying His Voice. (Exo.23:23) For mine angel shall go before thee, and bring thee in unto the Amorite, and the Hittite, and the Perizzite, and the Canaanite, the Hivite, and the Jebusite: and I will cut them off. These are the original inhabitants of the land. They represent the lusts of the flesh that live in our Promised Land right here, and the Lord is going to lead us to sanctification from every one of these lusts. Each group of these original inhabitants represents the old man ruled over by demon gods with matching specialties and each of their names has a meaning. “Canaanite” means “to bend the knee, to humiliate, to subdue.” “Amorite” means “prominent,” and of course, one of the evils of the flesh is pride. “Hittite” means “terror, fear.” There are many different kinds of demons of fear, and God wants to deliver us from all kinds of fear. Your flesh fears many things; you could have a fear of rejection or a fear of heights and so on. “Perizzite” means “to separate.” Think about it; religions separate from religions and nations separate from nations. Factions separate. When religions separate from each other, it's “sectarianism,” which Paul listed among works of the flesh. (Gal.5:19) Now the works of the flesh are manifest, which are [these:] fornication, uncleanness, lasciviousness, (20) idolatry, sorcery, enmities, strife, jealousies, wraths, factions, divisions, parties, (21) envyings, drunkenness, revellings, and such like… Paul called them “lusts of the flesh”; we call them “denominations.” And countries naturally have a bias toward the people who live in their nation, but we are not supposed to be divided from Christians anywhere in the world. We are a holy nation (1 Peter 2:9). We are “one man in Christ Jesus.” (Gal.3:28) There can be neither Jew nor Greek, there can be neither bond nor free, there can be no male and female; for ye all are one [man] in Christ Jesus. That means a Christian over in Russia is my brother; I am not going to fight for America to kill a Christian over in Russia, or anywhere else. It is wrong! This is worldly thinking and we need to understand that Jesus said, (Joh.18:36) My kingdom is not of this world… We are one holy nation, so no matter where on earth we are living, we are supposed to be a part of (Heb.12:22) … the city of the living God, the heavenly Jerusalem. “Jebus” was the old name for Jerusalem, and it's interesting that “Jebusite” means “trodden down.” The Bible says that Jerusalem will be “trodden down.” (Luk.21:24) Jerusalem will be trodden down of the Gentiles, until the times of the Gentiles be fulfilled. Revelation 11 talks about the outer court being trodden down. (Rev.11:2) And the court which is without the temple leave without, and measure it not; for it hath been given unto the nations: and the holy city shall they tread under foot forty and two months. Jesus told us in (Mat.5:13) Ye are the salt of the earth: but if the salt have lost its savor, wherewith shall it be salted? it is thenceforth good for nothing, but to be cast out and trodden under foot of men. It's the old Jerusalem, not the New Jerusalem, who is going to be trodden down. Old, unregenerate Jerusalem was Jebus. They were trodden down that New Jerusalem could take their place. Going on in (Exo.23:24) Thou shalt not bow down to their gods, nor serve them, nor do after their works… Notice two things in this verse: “their gods” and “their works.” If you live after the lusts of your flesh, that is your works, and if you “bow down to their gods,” then you're being ruled by demons. It says in (1Co.10:20) But [I say,] that the things which the Gentiles sacrifice, they sacrifice to demons, and not to God: and I would not that ye should have communion with demons. You see, every one of the lusts of the flesh has a demon spirit that rules over it. Jesus Christ sowed a Seed in us to bring forth the fruit of the Spirit, but the demons have sown other seeds in mankind. They have sown seeds of anger, seeds of lust, and seeds of rebellion, and the flesh has been bringing forth what is called the “lusts” of the flesh, which is another way of saying “fruit” of the flesh (Galatians 5:19-21; 2 Peter 2:10-19). Demons are the ones who sowed the seeds that have brought this forth. They are the gods of the lusts of the flesh and God commanded us to kill them and not to serve their gods. (Exo.23:33) They shall not dwell in thy land, lest they make thee sin against me; for if thou serve their gods, it will surely be a snare unto thee. He is talking about marching through this Promised Land, and putting to death, one by one, the lusts of the flesh. And He is talking about not submitting, not bowing down, to their gods. If you are throwing out their “flesh,” you are throwing out the demon gods' power. If you simply throw out the demon gods and hold on to the flesh, they will be back. We are this Promised Land that has to be sanctified. The word “sanctified” means “separated from sin, separated from the curse, and separated unto God.” As God led the Israelites through their Promised Land and they put to death the original inhabitants with a physical sword, so we are led of the Holy Spirit through our promised land to put to death the lusts of the flesh with the “sword” of the Spirit, which is the Word of God. (Heb.4:12) For the word of God is living, and active, and sharper than any two-edged sword, and piercing even to the dividing of soul and spirit, of both joints and marrow, and quick to discern the thoughts and intents of the heart. And it is two-edged because one edge is for you. We are commanded to Put to death therefore your members which are upon the earth: fornication, uncleanness, passion, evil desire, and covetousness, which is idolatry. (Col.3:5) The devil fears you if you know your authority and you are walking with God. Now, what about casting out demons from the lost? Are we authorized to do that? One time, I had been asking God about casting demons out of my mother. She had come to live with us in our house, but she didn't know the Lord. Most people do not know you need permission from God to cast demons out of a lost person, but it's biblical. (Luk.11:24) The unclean spirit when he is gone out of the man, passeth through waterless places, seeking rest, and finding none, he saith, I will turn back unto my house whence I came out. (25) And when he is come, he findeth it swept and garnished. (26) Then goeth he, and taketh [to him] seven other spirits more evil than himself; and they enter in and dwell there: and the last state of that man becometh worse than the first. You see, the lost person will get them seven times worse if you cast the demons out without the person turning to God. There are “loopholes” in the Bible, and so I asked God for permission to cast the demons out of my mother on the basis that my house is not cursed, but she was in my house and bringing me under a curse. I asked, “God, I am not under the curse. Can I cast the demons out of her because she is bringing a curse upon me?” God gave my daughter Jennifer a dream that night. She saw my mother's house in the middle of my house, except it was three stories tall, sticking out of the top of my house. Out of the second floor, representing the soul, there was a plank leading out to the street. Five chickens, representing unclean spirits, were on it and they were walking the plank to the street. Well, I knew exactly what the Lord was saying. That night, Mama, full of demons, came to our bedroom door and her demons threatened us, “I am going to keep you awake all night!” I said, “Oh no you're not!” My wife and I jumped up and went into her room, and as we stood there, God gave us five spirits to cast out. We didn't even wait to see them come out. We just commanded, “Come out in the Name of Jesus!” as fast as we could name them. Then we marched out, went back to bed, and slept peacefully all night. The next day, we noticed that it was awfully quiet in that room. Not knowing what was going on, we opened the door and peeked in to see that her room was a total mess. And there was my mother, crawling out from under the bed! She had been wrestling in there with something all night long, but when she came out, she was humble, meek, and submissive. I never knew my mother to be that kind of person. She had been demon-possessed all of her life; she had been taking medication all of her life to keep those demons in subjection. Her “religion” had kept her from turning to God when she had the opportunity, but as long as she was in my house, we had peace. When the demons started drifting back, the Lord took her out of my house. As she was dying she returned to peace. There are several reasons why God will give deliverance to the lost, and we should read the Bible like a lawyer because God put loopholes in there so you can step through them sometimes. Another great loophole that the Lord showed me is that if somebody is a blessing to you, you can be a blessing to them. It does not matter if they are lost. We have the example of when Paul was shipwrecked on Melita and the natives of the island came to the rescue. They were very kind to Paul and the others who were cold and wet. The natives dried their clothes and got them out of the rain (Acts 28:1-2). (Act.28:7) Now in the neighborhood of that place were lands belonging to the chief man of the island, named Publius, who received us, and entertained us three days courteously. (8) And it was so, that the father of Publius lay sick of fever and dysentery: unto whom Paul entered in, and prayed, and laying his hands on him healed him. He never preached the Gospel to him; he just healed him. Then they brought all the sick people on the island to Paul. He prayed for them and God healed them. (Act.28:9) And when this was done, the rest also that had diseases in the island came, and were cured. You do not see this elsewhere in the Bible because “healing is the children's bread” (Matthew 15:26), so I asked, “Why is this, Lord?” The Lord answered, “They were kind to them.” God will let you pray for somebody and heal them because they were good to you. He said, (Gen.12:3) And I will bless them that bless thee, and him that curseth thee will I curse: and in thee shall all the families of the earth be blessed. This is talking about us; we are the “Israelites.” There's one loophole, too, that's the mercy of God. The demoniac described in the Gospels was so far gone that you could not expect the man to have faith or make a rational decision, and Jesus cast the demons out of him, knowing what kind of decision he was going to make afterward (Matthew 8:28-34; Mark 5:1-20; Luke 8:26-39). Sometimes God does this, but He does not have to do it. Now let me share with you the following testimony: Delivered from Scoliosis by D. M. My brother-in-law once bought me a book by Henry W. Wright entitled “A More Excellent Way: A Teaching on the Spiritual Roots of Disease.” I found the book to be fascinating and, as the British say, “spot-on” in many ways. (There is definitely a connection between a sin and its curse. Quite often, a sickness can identify the sin.) I have a good friend named “A” whom I've known since I was saved. We have conversed via phone for years, since we live in different states. A couple of years ago, he mentioned that he'd had scoliosis since childhood. I didn't say anything to him, but I went to Henry Wright's book and looked up what he had to say about scoliosis. I kept this to myself because I didn't feel right bringing it up to “A.” I knew the time would come as the Lord gave me freedom to do so. Today, I received an email from “A” asking me to pray for him for deliverance from a particular sin. He did not go into detail but gave me a hint. I replied that I would pray for him in a moment. But first I wanted to know when his scoliosis had begun, and if, in fact, it had begun about the time of his traumatic incident. He replied back that it did begin right afterwards. I decided to give him a call. We talked. He made a full confession of the incident. I quoted (Jas.5:16) Confess therefore your sins one to another, and pray one for another, that ye may be healed. The supplication of a righteous man availeth much in its working. And I told him that there was now nothing in the way of his deliverance. I prayed over the phone with him in agreement. Glory be to God, a hundred-pound weight came off my friend and he was delivered from the evil spirit of scoliosis and was healed! Awesome! Praise the Lord! Saints, we need to be led of the Spirit and wait for the Lord's leading so He can open the way for us to minister to others. Here's another testimony I'd like to share with you. Delivered from Lung Cancer by Linda L. (This lady was healed of a spirit of cancer when I for the brethren in our meeting rebuked it, although she was not present at that meeting. She related to us how, later that same night, what looked like smoke came out of her nose and she knew she was healed. Please note that she had faith to be healed.) My doctor's office called to tell me I had an inconsistency on my chest x-ray. I needed to go to the hospital for another x-ray. The second x-ray was not any better than the first. A CT scan was ordered. The suspicious spot was a ten-centimeter (approximately two inches) sized nodule in the upper right lobe. That night after numerous internet searches, I was devastated to learn that most nodules are malignant. My father had died of lung cancer in 1998. I am very familiar with the disease. At this point I started to do a lot of praying. Even though I knew Jesus heard my prayer, I did not have peace yet. My doctor sent me to a pulmonary specialist. The first thing Dr. Wagner told me was that I was not to worry. The surgeon would remove my lobe. I would not have to undergo chemotherapy or radiation. He started to ask questions about health, lifestyle, etc., and we talked more. He decided to wait and repeat the CT scan in two months. At this point, I told Dr. Wagner that God would heal me. He did not say anything, but I am sure he thought I was deluded. I am a very reserved person. I usually do not share information of this nature with many people. However, the Holy Spirit prompted me to tell Dr. Wagner how Jesus would heal my lung. When I saw Bob, a UBM elder, I told him my predicament. And as we talked, I asked his group to pray for my healing. Jesus would heal me. This was a Tuesday. I did not see Bob during the week, but I KNOW his prayer group prayed for me. A peace beyond all understanding came over me Saturday night. During the middle of the night, I saw an evil spirit leave my lungs! I KNEW I was healed. The next month arrived. It was time to repeat the CT scan. The doctor at the Imaging Center observed the entire scan. He reported the nodule was starting to calcify. In his opinion the nodule was now benign. Tears and praise flowed, as Jesus had healed me. Dr. Wagner told me I was one lucky lady. I reminded him that Jesus would heal me. The doctor did not acknowledge anything yet, but he knows that this healing from a deadly lung nodule was a miracle. Jesus hears our prayers and heals those who ask and have faith. He knows our pain. He honors His commitment to us when we believe Him and the works of His hands. Amen! That's so true! Praise You, Lord! Let's look at this parable in the Old Testament, how God delivers us. The Lord says in (Exo.23:27) I will send my terror before thee, and will discomfit all the people to whom thou shalt come, and I will make all thine enemies turn their backs unto thee. (28) And I will send the hornet before thee, which shall drive out the Hivite, the Canaanite, and the Hittite, from before thee. You know, it's easy to win a battle when your enemy is afraid, and making your enemy fearful is a proven strategy of warfare. There have been great battles won by very small armies against very large armies, all because fear was in the larger army. This happened to Israel in the 1967 Arab-Israeli War when Arabs attacked them from all sides. Israel won overwhelming victories against all odds because God put fear in the hearts of their enemies. It's a quick battle when the enemy is fearful. Only God is able to do this! He did this in many places in the Scriptures, giving the Israelites tremendous victories. We have a good example where they sent spies into the Promised Land to understand their enemies' thinking. (Jos.2:1) And Joshua the son of Nun sent out of Shittim two men as spies secretly, saying, Go, view the land, and Jericho. And they went and came into the house of a harlot whose name was Rahab, and lay there… (8) And before they were laid down, she came up unto them upon the roof; (9) and she said unto the men, I know that the Lord hath given you the land, and that the fear of you is fallen upon us, and that all the inhabitants of the land melt away before you. (10) For we have heard how the Lord dried up the water of the Red Sea before you, when ye came out of Egypt… Going through the Red Sea was their salvation experience. Guess who knows immediately about our salvation experience? Demon spirits. They know who we are, but the problem is not that they know; the problem is, do we know? This is why we need to study the Scriptures; it's important that we find out who we are. Unless we know who we are, demon spirits can, and do, take advantage of us, but when you know who you are according to Scripture, the demons are fearful. In the dream that the Lord gave my daughter, the Lord had a sense of humor because He pictured the five demons as five chickens. Our enemies know that they cannot keep us from taking our land. (Jos.2:10) For we have heard how the Lord dried up the water of the Red Sea before you, when ye came out of Egypt; and what ye did unto the two kings of the Amorites, that were beyond the Jordan, unto Sihon and to Og, whom ye utterly destroyed. (11) And as soon as we had heard it, our hearts did melt, neither did there remain any more spirit in any man, because of you: for the Lord your God, he is God in heaven above, and on earth beneath. All of these verses are types and shadows of our enemies being fearful of us. (Jos.1:5) There shall not any man be able to stand before thee all the days of thy life: as I was with Moses, so I will be with thee; I will not fail thee, nor forsake thee. (6) Be strong and of good courage; for thou shalt cause this people to inherit the land which I sware unto their fathers to give them. (7) Only be strong and very courageous, to observe to do according to all the law, which Moses my servant commanded thee: turn not from it to the right hand or to the left, that thou mayest have good success whithersoever thou goest. (8) This book of the law shall not depart out of thy mouth, but thou shalt meditate thereon day and night, that thou mayest observe to do according to all that is written therein: for then thou shalt make thy way prosperous, and then thou shalt have good success. Spiritually speaking, the Lord is talking about taking this “land” in which we live, taking this land of the soul, which is our mind, our will, and our emotions. God says, (Exo.23:29) I will not drive them out from before thee in one year, lest the land become desolate, and the beasts of the field multiply against thee. From this example, we see that it is not God's plan to purify us instantly, but almost every Christian religion teaches some form of “instantaneous sanctification.” They say all you need to do is get saved and you're sanctified. A number of them also believe that you're automatically filled with the Holy Spirit. In other words, there's a line you just step over and that's all there is to it; then you can sit down and take it easy. No, we can never sit down and take it easy because we have a land to conquer. God goes on to say, (Exo.23:30) By little and little I will drive them out from before thee, until thou be increased, and inherit the land. “Little by little” is God's plan. People who have their “instantaneous sanctification” theology do not understand that sanctification is when you are delivered of all the lusts of the flesh to the point where you're not even going to be tempted anymore. The ultimate end of sanctification is when the flesh is dead. We can all think of things in our lives from which God delivered us. They do not even tempt us anymore because that flesh is dead, but God wants to continue that process until He goes through all of our “Promised Land.” God wants to lead you to your enemy, give you the Sword of the Spirit (Ephesians 6:17), and put the fear of God in you (Psalms 111:10; Proverbs 1:7; etc.) He wants to give you understanding to know that you have victory through the Gospel and through the Blood of Jesus. So the Lord said, (Exo.23:22) But if thou shalt indeed hearken unto his voice, and do all that I speak; then I will be an enemy unto thine enemies, and an adversary unto thine adversaries. But He also says, (Exo.23:29) I will not drive them out from before thee in one year… and (Exo.23:30) By little and little I will drive them out from before thee… Well, the people of Israel did not “hearken unto his voice” to do all that the Lord spoke. We read in (Jdg.21:25) In those days there was no king in Israel: every man did that which was right in his own eyes. (Jdg.2:20) And the anger of The Lord was kindled against Israel; and he said, Because this nation have transgressed my covenant which I commanded their fathers, and have not hearkened unto my voice; (21) I also will not henceforth drive out any from before them of the nations that Joshua left when he died; (22) that by them I may prove Israel, whether they will keep the way of The Lord to walk therein, as their fathers did keep it, or not. (23) So the Lord left those nations, without driving them out hastily; neither delivered he them into the hand of Joshua. If you break God's Covenant, He is not going to do a quick work of delivering your enemies into your hand. The Blood is our weapon to cleanse us from all unrighteousness. The New Testament says, (1Jn.1:7) But if we walk in the light, as he is in the light, we have fellowship one with another, and the blood of Jesus his Son cleanseth us from all sin. (8) If we say that we have no sin, we deceive ourselves, and the truth is not in us. (9) If we confess our sins, he is faithful and righteous to forgive us our sins, and to cleanse us from all unrighteousness. The Blood cleanses as we walk in the light and as we obey what we know to obey. We cannot do anything about what we do not know, but as we do what we know to obey, the Blood cleanses. These “lusts of the flesh” and their “gods,” which have the same names, have to be driven out. Every lust of the flesh has a “god.” It's the demon spirit, having the same name, that rules over that particular lust. God said He is not going to be in a hurry to drive out your enemies if you are going to rebel. The Bible says in (Luk.12:48) And to whomsoever much is given, of him shall much be required. If you do something with what God gives you, He will give you more, but if you do not do something with what He has already given you, He is not going to give you anymore. You're going to stop right in your tracks because God is a merciful God. Otherwise, you would be condemned for not doing even more, and so when you stop doing something with your Sword against your enemy, God is going to stop. God does not flood us with knowledge of our every evil. He leads us to each individual evil, step-by-step, and He expects us, at that point and time, to do something about it. If He were to just flood our minds with the knowledge of all of the evil in us, we would be overwhelmed and probably lose faith. And if we didn't do something with all that knowledge, we would be condemned. When you have a lot of knowledge, Scripture warns us, (Jas.4:17) To him therefore that knoweth to do good, and doeth it not, to him it is sin. When you have a lot of knowledge, yet do nothing, you have a lot of sin. God brings these enemies up, one at a time, in front of our face. This usually occurs through temptation, through something happening around us. When He brings these enemies up in front of our face, we have an opportunity to use the Sword to come against that enemy. We can reject that lust of the flesh and command it to go in the Name of Jesus. If there is any demon spirit in our flesh, or if there is any demon spirit using that lust of the flesh to exercise authority in our soul, we can come against it, and we can win right there. We do not have to live with these demons all of our lives or go searching for some deliverance ministry, because we have authority over demon spirits and the flesh (Matthew 28:18-19; Luke 10:19; etc.) We're told, (Rom.6:11) Even so reckon ye also yourselves to be dead unto sin, but alive unto God in Christ Jesus. This is what we have to believe. We are dead unto sin, but alive unto God. We have total authority over the Hittites, the Girgashites, the Hivites, the Canaanites, and so forth. We have total authority over them and their gods. Every one of us can learn to exercise our Sword, the Word, against the lusts of the flesh and those spirits. We don't have to live with them anymore, but God is only going to continue this process as long as we cooperate. We are here to conquer our Promised Land, and there's no time for us to rest in the flesh. Our rest is in the Spirit. Our rest is in the promises of God. We can safely rest in His Word. The quicker we submit to him and resist the devil, the quicker we win. It says in (Psa.81:10) I am the Lord thy God, Who brought thee up out of the land of Egypt (He delivered you from the power of the old man at the Red Sea baptism.): Open thy mouth wide, and I will fill it. That is, “Say what I say,” speak as an oracle of God (1 Peter 4:11). And (11) But my people hearkened not to my voice; And Israel would none of me. (12) So I let them go after the stubbornness of their heart, That they might walk in their own counsels. (13) Oh that my people would hearken unto me, That Israel would walk in my ways! (14) I would soon subdue their enemies (If we obey and fight the enemy, we will “soon” win.), And turn my hand against their adversaries. And they will be conquered. (15) The haters of the Lord should submit themselves unto him: But their time should endure for ever. (16) He would feed them also with the finest of the wheat; And with honey out of the rock would I satisfy thee. It's our obedience that brings the blessings. Remember, we are to be vigilant when we are in a trial because it's our opportunity to come against that particular enemy in our Promised Land and win. God brought us to this enemy for us to conquer it, and to do it now. This is why we are here. He has given us total authority over that enemy. There is no such thing as a “giant” in our Promised Land since even the least of us has total authority over the mightiest demon that comes into contact with us. God is walking with you. You need to realize that He wants your enemies to be conquered here and now, day by day, little by little. (Psa.81:11) But my people hearkened not to my voice; And Israel would none of me. (12) So I let them go after the stubbornness of their heart, That they might walk in their own counsels. You see, if you're resting in the flesh, rather than resting in the Spirit, then you are not doing anything. We are here to redeem the time and to win a battle. (Eph.5:15) Look therefore carefully how ye walk, not as unwise, but as wise; (16) redeeming the time, because the days are evil. (17) Wherefore be ye not foolish, but understand what the will of the Lord is. What is His Will for us if we walk in His ways? (Psa.81:13) Oh that my people would hearken unto me, That Israel would walk in my ways! (14) I would soon subdue their enemies, And turn my hand against their adversaries. You may say, “Well, David, that's exactly my problem, walking in His ways,” but there is always a step you can take, however small it may be. If He makes us responsible to walk in His ways, then we can walk in the light. (1Jn.1:7) But if we walk in the light, as he is in the light, we have fellowship one with another, and the blood of Jesus his Son cleanseth us from all sin. We can take those steps. (Pro.4:18) But the path of the righteous is as the dawning light, That shineth more and more unto the perfect day. You can take one step at a time, and God will be with you each step.

Lung cancer has a high chance of relapse, so how do we get out of ahead of it? Nancy Guo, SUNY Empire Innovation Professor in the school of computing at Binghamton University, discusses technology that helps us do so. Nancy Guo is one of the newest additions to the Binghamton University School of Computing as […]

In episode 90 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Brandon Leum, Founder of @buildingarefuge. Tune in as Brandon shares the organization's mission to bring hope and encouragement to men through meetings, events, and the BAR Podcast. You can connect with Building a Refuge at buildingarefuge.org.

Dr. Arif Ali is a board-certified radiation oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of deaths because it is often diagnosed too late. A new screening program has become available that hopes to detect cases much earlier for those at the highest risk - which includes Indigenous Australians and some migrant communities.

Humans have long been exposed to three main types of smoke: from early domestic fires, modern wildfires, and more recently, tobacco and fossil fuel pollution. All release tiny particles from partly burned plants, containing harmful chemicals like nitrogen oxides and carcinogens. These particles raise risks for lung cancer, dementia, and even childhood obesity. Studies show that air pollution can disrupt brain chemistry, increase Alzheimer's-related proteins, and activate stress-related genes (NFkB, Nrf2). A new drug (GSM-15606) shows promise in reducing brain damage from pollution in mice. People with the ApoE4 gene may be more vulnerable, while the ApoE3 gene, possibly evolved 200,000 years ago, may offer some protection. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40700]

“Just remember that these patients, these are human beings who had lung cancer. It's a scary disease. And we don't want to just say, ‘Oh, well, that's a horrible disease. They probably won't do well.' These patients are living longer. Our treatments are better. And so no matter who they are, they have every chance of surviving long term for this,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 27, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer survivorship. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Nursing Considerations for Lung Cancer Survivorship Care Nurse-Led Survivorship Programs: Expert Advice to Help You Build Your Institution's Resources Oncology Nursing Forum articles: Empowering Lung Cancer Survivors in Post-Treatment Survivorship Care Using Participatory Action Research A Qualitative Cultural Sensitivity Assessment of the Breathe Easier Mobile Application for Lung Cancer Survivors and Their Families Exploring Stigma Among Lung Cancer Survivors: A Scoping Literature Review ONS Survivorship Care Plan Huddle Card ONS Survivorship Learning Library To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “For patients with stage I disease, they have a pretty good chance of getting to that five-year mark, somewhere probably in the 70%–80% range, depending on if you're stage IA or IB. Then it starts to drop obviously if you go up stages with patients.” TS 6:36 “Our radiation oncologists … and the dosimetrists in radiation oncology do a great job trying to line those beams up to minimize toxicity to those other vital organs. But we just can't always do that. You may see long-term fibrotic changes within the lungs. You could see cardiac damage over time. You can see esophagitis or [gastrointestinal] toxicity, particularly in the esophagus over time, post-radiation. And just the fact of having disease or cancer in the lungs, you can have breathing problems and pulmonary issues long term.” TS 10:37 “Part of survivorship in lung cancer is smoking and smoking cessation. I know it can be hard for people to quit, even people who had curative-intent treatment for their lung cancer—and so keeping up with smoking cessation. And that can be hard again if you don't have access to a smoking cessation specialty or if you live with other people who smoke and don't have really access to programs to help you quit and help you stay quitting.” TS 17:26 “I should talk about autoimmune diseases as part of immunotherapy. We give immunotherapy now in the curative setting preoperatively, postoperatively, post-chemoradiation, so they may get a year or so of immunotherapy. They may develop some sort of autoimmune toxicity from that. Usually that will go away once we stop the immunotherapy. But I've seen some things persist over time. That can go anywhere from like mild eczema that came about to things like more serious, like maybe lupus or scleroderma that may have developed as part of your immunotherapy. And we may stop the immunotherapy, but that may linger on.” TS 25:02  

Since that first interview, Richard has faced multiple cancer recurrences—including brain tumors and cancer in his remaining lung—and continues to rely on cannabis oil as a central part of his healing. In this episode, he talks candidly about living with cancer, navigating the challenges of legalization, dealing with skeptical doctors, and staying grounded with family, humour, and positivity.00:37 – Introduction to Richard Lusk and his original interview from 201601:17 – How Richard first discovered his lung cancer02:45 – Starting cannabis oil and watching tumors shrink03:45 – Leaving Washington to care for his mother in Kansas—cannabis access cut off04:30 – Cancer returns and spreads to his brain05:38 – Returning to Washington for treatment and cannabis access06:10 – Telling his oncologist about cannabis oil07:02 – Doctors say it's incurable—Richard disagrees07:53 – How he takes a gram of cannabis oil each day08:54 – Symptoms that led to brain tumor discovery09:39 – Years in construction and staying physically resilient10:28 – Emotional vs. physical challenges of illness11:40 – Thoughts on legal cannabis access across the U.S.12:57 – Adrenal gland cancer and additional surgeries13:44 – Belief in cannabis over conventional treatments16:07 – The role of cannabis in surviving cancer17:40 – Advice for people newly diagnosed with cancer18:41 – Staying positive and the importance of family20:52 – Choosing your own path despite family opposition21:12 – Current restrictions and chemo side effects22:48 – Gratitude for life and simple pleasures23:26 – A brain surgeon's 6.5 rating and Richard's humour24:38 – Final thoughts, hope for change, and sharing his story Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

Imagine being told you only have 12 months to live. What would you do with your time? Today on Your Money, Your Wealth podcast number 532, Big Al Clopine, CPA and Executive Producer Andi Last are thrilled to welcome Jonathan Clements back for his fourth appearance. For thirty years, Jonathan has been known for his personal finance writing: in his column “Getting Going,” which appeared in the Wall Street Journal over 1,000 times starting in 1994, on his website HumbleDollar.com, and in his many acclaimed books. About a year ago, Jonathan Clements was diagnosed with a rare form of lung cancer and was told he had about a year to live. Today we're celebrating the fact that he is still here with us, and we're inspired by his decision to use his precious time to launch The Jonathan Clements Getting Going on Savings Initiative. Watch or listen to find out how you can get a free Kindle copy of Jonathan's new book, and how you can help Jonathan pay it forward for the next generation. Free financial resources & episode transcript: https://bit.ly/ymyw-532 The first 100 people to email us will receive a free Kindle copy of The Best of Jonathan Clements: Classic Columns on Money and Life WATCH Retirement Sabotage! 12 Post-Retirement Money Mistakes to Avoid on YMYW TV ASK Joe & Big Al for your Retirement Spitball Analysis SCHEDULE your Free Financial Assessment SUBSCRIBE to YMYW on YouTube DOWNLOAD more free guides READ financial blogs WATCH educational videos SUBSCRIBE to the YMYW Newsletter Timestamps:  00:00 - Intro: This Week on the YMYW Podcast 02:53 - Jonathan Clements' Getting Going on Savings Initiative 05:23 - $1,000 Roth IRA Contributions and Personal Finance Education for Young Adults 07:55 - Exponential Growth: The Sooner You Save, The Better 09:44 - Research Study Will Measure Impact on Young Savers 11:56 - Financial Education is Important 14:05 - The John C. Bogle Center for Financial Literacy 14:38 - The First 100 People to Email Us Receive a Free Copy of The Best of Jonathan Clements: Classic Columns on Money and Life 15:45 - How Does a Healthy 62-Year-Old Non-Smoker End Up Living With Stage IV Lung Cancer? The EGFR Exon 20 Insertion Mutation 18:52 - HumbleDollar.com, The Jonathan Clements Getting Going on Savings Initiative, and The Best of Jonathan Clements Book